| Feature | Terlipressin | Vasopressin | Somatostatin |
|---|---|---|---|
| Selectivity | V1-selective | Non-selective (V1 + V2) | Somatostatin analogue |
| Systemic effects | Minimal | Significant (coronary vasoconstriction) | Minimal |
| Mortality benefit | Yes (proven) | Equivocal | Equivocal |
| First-line status | Yes | No (obsolete) | Alternative |
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.
Daily MCQs, study tips, and topper strategies on Telegram.
Join on Telegram →